Adamis Pharmaceuticals Corporation Stock News

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx Says FDA Committee Casts Negative Vote On ALS Drug Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -8.70% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid ove

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overd

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer Merck & Co., Inc. (NYSE: MRK) s

Tempol Reduced Lung Inflammation After High Dose Challenge Tempol Reduced Lung Inflammation After High Dose Challenge

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level.  The

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and

A Data Safety Monitoring Board has determined that Adamis Pharmaceuticals'' (ADMP) phase 2/3 trial for its COVID-19 candidate tempol can continue without any changes.

DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue